EGFR and lung carcinoma: Alterations in the pocket protein pathway identify EGFR mutant lung cancer patients that have worse outcomes on this therapy (Niederst et al., 2015; Jiang et al., 2016; Blakely et al., 2017; Lee et al., 2017; Marcoux et al., 2019; Skoulidis and Heymach, 2019; Liu et al., 2021).